Fig. 3. Therapeutic efficacy of nanovaccine for eradicating pre-existing tumours in mice.
a–e, Tumour volume measured at different timepoints post s.c. injection of pErNP–OVA–CPG B (n = 17), OVA alone (n = 8), pErNP–OVA (n = 8), PBS (n = 8) and OVA mixed with CpG B (n = 5) respectively. n is the number of mice used for each group. f, Per cent survival graph of each animal groups treated in a–e. g,h, Photographs of E.G7–OVA tumour-bearing mice recorded on various days post tumour inoculation (−4 days) and treated on the same 0 day by pErNP–OVA–CpG B or PBS. i, Ex vivo photos of the solid tumours of pErNP–OVA–CpG B immunized and PBS-treated group taken on day 7.